BIO, Senate plans would expedite FDA approval for some drugs

Senate proposals would allow drug manufacturers to bypass some clinical-trial requirements and get faster FDA approval of medications for conditions that do not have approved treatments. The plans, by Sen. Kay Hagan, D-N.C., and BIO, are based on the FDA’s accelerated-approval program and would let the agency approve drugs based on Phase II trial results. Bloomberg (11/16)

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s


%d bloggers like this: